drugset / Trial / NCT07832630
Saruparib in HRDsig+ Solid Tumors
Phase 2
Not yet recruiting
124 enrolled
Abramson Cancer Center at Penn Medicine
AstraZeneca · collabBasser Center for BRCA · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to study the effect of saruparib, an experimental PARP inhibitor, on tumors that have an Homologous Recombination Deficiency Signature (HRDsig) positive tumor by the investigational FoundationOne®CDx clinical trial assay.
Timeline
- Start
- 2026-11-01
- Primary completion
- 2029-11-01
- Completion
- 2030-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Saruparib | Small molecule | 60 mg | Oral |